Caris Life Sciences (NASDAQ:CAI) Upgraded to Strong-Buy at Robert W. Baird

Caris Life Sciences (NASDAQ:CAI) was upgraded by investment analysts at Robert W. Baird to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Evercore set a $38.00 target price on Caris Life Sciences in a research report on Monday, January 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Caris Life Sciences presently has an average rating of “Hold” and an average price target of $31.33.

Caris Life Sciences Stock Up 0.9%

CAI opened at $20.80 on Tuesday. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79. The company has a market cap of $5.87 billion and a price-to-earnings ratio of -45.22. The stock’s fifty day moving average is $25.67. Caris Life Sciences has a fifty-two week low of $20.27 and a fifty-two week high of $42.50.

Insider Buying and Selling at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the sale, the insider owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This trade represents a 38.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Hedge Funds Weigh In On Caris Life Sciences

A number of hedge funds have recently made changes to their positions in CAI. Global Retirement Partners LLC boosted its position in shares of Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares in the last quarter. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $31,000. MetLife Investment Management LLC raised its holdings in shares of Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after buying an additional 755 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $67,000. Finally, Federated Hermes Inc. acquired a new stake in Caris Life Sciences in the 4th quarter valued at $81,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.